List of Nurtec Odt drug patents

Nurtec Odt is owned by Biohaven Ireland.

Nurtec Odt contains Rimegepant Sulfate.

Nurtec Odt has a total of 3 drug patents out of which 0 drug patents have expired.

Nurtec Odt was authorised for market use on 27 February, 2020.

Nurtec Odt is available in tablet, orally disintegrating;oral dosage forms.

Nurtec Odt can be used as acute treatment of migraine with or without aura in adults; preventive treatment of episodic migraine in adults.

Drug patent challenges can be filed against Nurtec Odt from February, 2024.

The generics of Nurtec Odt are possible to be released after 25 March, 2039.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8314117 BIOHAVEN IRELAND CGRP receptor antagonists
Feb, 2031

(8 years from now)

US8759372 BIOHAVEN IRELAND N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt
Feb, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11083724 BIOHAVEN IRELAND Rimegepant for CGRP related disorders
Mar, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 27, 2025
New Indication (I) May 27, 2024

Drugs and Companies using RIMEGEPANT SULFATE ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 27 February, 2020

Treatment: Acute treatment of migraine with or without aura in adults; Preventive treatment of episodic migraine in adults


More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in